Cerevel Therapeutics (NASDAQ:CERE) Downgraded to Neutral at Cantor Fitzgerald

Cantor Fitzgerald cut shares of Cerevel Therapeutics (NASDAQ:CERE – Free Report) from an overweight rating to a neutral rating in a report issued on Thursday, MarketBeat reports. Cantor Fitzgerald currently has $45.00 price objective on the biotechnology company’s stock, up from their previous price objective of $38.00. A number of other brokerages have also recently […]

Leave a Reply

Your email address will not be published.

Previous post Braze (NASDAQ:BRZE) Given New $65.00 Price Target at DA Davidson
Next post H&R Block (NYSE:HRB) Lowered to “Hold” at StockNews.com